반다파마슈티컬스(VNDA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $5.13 (+0.39%), 시가총액 $0.38B, 52주 최저~최고 $3.92 ~ $9.56.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for
반다파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
반다파마슈티컬스의 현재 주가는 $5.13 (+0.39%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
반다파마슈티컬스의 시가총액은 약 $0.38B입니다.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio